Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies

INTRODUCTION: Advanced hepatocellular carcinoma (HCC) represents a major public health threat. Several emerging combination therapies have shown promising results for the first-line treatment of advanced HCC. The present study compared the efficacy of atezolizumab plus bevacizumab (AB) with lenvatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yawen, Cai, Dan, Shi, Si
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064682/
https://www.ncbi.nlm.nih.gov/pubmed/35520275
http://dx.doi.org/10.2147/CLEP.S352045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9064682/
https://www.ncbi.nlm.nih.gov/pubmed/35520275
http://dx.doi.org/10.2147/CLEP.S352045

Ejemplares similares